China Resources Pharmaceutical Group (STU:640) ROE % Adjusted to Book Value: 16.21% (As of Dec. 2025)


STU:640 China Resources Pharmaceutical Group Ltd STU:640
63 GF Score
Price €0.49
GF Value €0.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group ROE % Adjusted to Book Value?

China Resources Pharmaceutical Group STU:640 +2.97% 63 ROE % Adjusted to Book Value is 16.21% as of Dec. 2025. GuruFocus rates STU:640 with a GF Score™ of 63/100 and a GF Value™ of €0.64 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China Resources Pharmaceutical Group's ROE % for the quarter that ended in Dec. 2025 was 7.78%. China Resources Pharmaceutical Group's PB Ratio for the quarter that ended in Dec. 2025 was 0.48. China Resources Pharmaceutical Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 16.21%.


China Resources Pharmaceutical Group ROE % Adjusted to Book Value Related Terms


China Resources Pharmaceutical Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for China Resources Pharmaceutical Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group ROE % Adjusted to Book Value Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.56 10.30 13.53 10.57 16.27

China Resources Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.16 16.22 4.60 14.50 16.21

STU:640 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's ROE % Adjusted to Book Value falls into.


STU:640
63GF Score
China Resources Pharmaceutical Group Ltd STU:640
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Pharmaceutical Group ROE % Adjusted to Book Value Calculation

China Resources Pharmaceutical Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=7.81% / 0.48
=16.27%

China Resources Pharmaceutical Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=7.78% / 0.48
=16.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 16.21% mean?
China Resources Pharmaceutical Group (STU:640) has a ROE % Adjusted to Book Value of 16.21% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's ROE % Adjusted to Book Value too high?
China Resources Pharmaceutical Group's current ROE % Adjusted to Book Value is 16.21%. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's ROE % Adjusted to Book Value compare to ZTS and UTHR?
China Resources Pharmaceutical Group's ROE % Adjusted to Book Value of 16.21% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current ROE % Adjusted to Book Value is 16.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current ROE % Adjusted to Book Value is 16.21%. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current ROE % Adjusted to Book Value is 16.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for STU:640:

  • ROE % Adjusted to Book Value: 16.21%
  • GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Resources Pharmaceutical Group Business Description

Other Exchanges 03320:Hong Kong
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score

Get the complete analysis for STU:640

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price
€0.64
GF Value